ArticleOncotarget2018

MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2.

Ming-Jenn Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.